Targets in the use of biologics for asthma
Asthma is a heterogeneous illness. Despite a vast array of treatment options, a significant proportion of patients with asthma continues to lack control of their illness. We now have a new class of asthma therapy in our armamentarium: biologic agents. Presently, the current pricing for all of the biologic agents exceeds measures of cost-effectiveness. Optimal patient selection, through phenotypic indices, is the only likely way to allow these agents to be cost effective. This review examined the literature regarding biologic agents, which stressed attempts at optimizing choice.
No References for this article.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: December 1, 2019
This article was made available online on August 20, 2019 as a Fast Track article with title: "Controversies in the management of venous thromboembolism".
More about this publication?
- The Journal of Precision Respiratory Medicine (JPRM) is a peer reviewed publication dedicated to distributing timely information regarding cutting edge advancements in the knowledge and practice of respiratory medicine. Its primary readership extends to all medical providers with an interest in respiratory diseases.
The incorporation of the term, 'precision medicine' in its title serves to direct the journal's focus on this revolutionary approach to disease prevention and treatment that takes into account the individual differences which result from the interplay of lifestyle, environment and human biology/genetics.
JPRM seeks to publish articles characterized by both a predominant clinical focus and by having the potential to directly impact the quality of patient care. JPRM welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Pulmonary Conference (EPC) JPRM will publish content from EPC poster sessions as well as review articles derived from EPC lectures.
Click on the fast track tab below to access new pre-publication articles.